Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human, randomized, doubleblind, placebo-controlled study to evaluate, single ascending doses of CIT-013 in healthy volunteers with and without an intravenous lipopolysaccharide challenge and repeat dosing in healthy volunteers and patients with Rheumatoid Arthritis

Next Previous
Trial Profile

A first-in-human, randomized, doubleblind, placebo-controlled study to evaluate, single ascending doses of CIT-013 in healthy volunteers with and without an intravenous lipopolysaccharide challenge and repeat dosing in healthy volunteers and patients with Rheumatoid Arthritis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CIT 013 (Primary) ; CIT 013 (Primary)
  • Indications Idiopathic pulmonary fibrosis; Rheumatoid arthritis; Systemic lupus erythematosus; Vasculitis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms CITRYLL001
  • Sponsors Citryll

Most Recent Events

  • 31 Jul 2024 According to a Citryll media release, company announced completion the successful completion of dosing in the repeat dose stage of its Phase 1 trial. Results are anticipated in Q4 2024, which, if positive, would lay the groundwork for the initiation of Phase 2a trials.
  • 15 Nov 2023 Results from part A presented at the ACR Convergence 2023
  • 29 Sep 2021 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top